Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD - PubMed (original) (raw)
Review
Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD
Sílvia Vilarinho et al. Hepatology. 2021 Oct.
Abstract
Whereas the rising prevalence of nonalcoholic fatty liver disease (NAFLD) is closely related with the global obesity epidemic, up to 10–20% of individuals with NAFLD are lean as defined by a body mass index of < 25 kg/m2, or < 23 kg/m2 in Asians. This entity designated as “lean NAFLD” is estimated to affect 8 to 10 million individuals in the United States alone. Here, we review the emerging data on the epidemiology, natural history and prognosis of lean NAFLD and put forward a diagnostic approach that combines detailed clinical phenotyping with genomic analysis. We propose two subtypes of lean NAFLD referred to as type 1: individuals with visceral adiposity and insulin resistance but normal BMI; and type 2: lean individuals with hepatic steatosis secondary to a known or unknown monogenic disease. We envision that incorporation of genomic analysis in the diagnostic algorithm of lean patients with NAFLD will elucidate the contribution of common genetic variants through the calculation of NAFLD polygenic risk score and also characterize the diverse array of rare monogenic diseases that can lead to triglyceride accumulation in the cytoplasm of hepatocytes. Collectively, the integration of a molecular diagnosis in the clinical evaluation of patients with lean NAFLD will provide an accurate diagnosis, with possible targeted therapies and may uncover novel molecular mechanisms with potential broader therapeutic implications.
Conflict of interest statement
Conflict of interests:
Potential conflict of interest for Rohit Loomba: Dr. Loomba serves as a consultant or advisory board member for Bird Rock Bio, Celgene, Enanta, GRI Bio, Madrigal, Metacrine, NGM, Sanofi, Arrowhead Research, Galmed, NGM, GNI, NovoNordisk, Merck, Siemens, Pfizer, Gilead. Glympsebio, In addition, his institution has received grant support from Allergan, BMS, BI, Daiichi-Sankyo Inc., Eli-Lilly, Galectin, Galmed, GE, Genfit, Intercept, Janssen Inc, Madrigal, Merck, NGM, Pfizer, Prometheus, Siemens, and Sirius. He is also co-founder of Liponexus Inc.
Figures
Figure 1:
Proposed diagnostic approach for uncovering underlying monogenic disorders in lean patients with NAFLD. aPatients with mitochondrial disorders may present with elevations in lactic acid levels upon minor physiological stressors (e.g., minor surgery, fever/infection). bDependent on the exact mitochondrial disorder, dietary guidance/supplementation may include avoidance of carbohydrate-rich foods or supplementation of different antioxidants, co-factors (e.g., arginine, CoQ10, L-carnitine).
Comment in
- Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort.
Park H, Yoon EL, Chung GE, Choe EK, Bae JH, Choi SH, Kim M, Hwang W, Kim HL, Yang SY, Jun DW. Park H, et al. Gut Liver. 2024 Mar 15;18(2):316-327. doi: 10.5009/gnl230044. Epub 2023 Aug 10. Gut Liver. 2024. PMID: 37560798 Free PMC article.
References
- Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:739–752. - PubMed
- Lu FB, Zheng KI, Rios RS, Targher G, Byrne CD, Zheng MH. Global epidemiology of lean non‐alcoholic fatty liver disease: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 2020. - PubMed
- Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112–117. - PubMed
- Davison BA, Harrison SA, Cotter G, Alkhouri N, Sanyal A, Edwards C, Colca JR, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. Journal of Hepatology 2020. - PubMed
Publication types
MeSH terms
Grants and funding
- K23 DK119460/DK/NIDDK NIH HHS/United States
- UL1 TR001442/TR/NCATS NIH HHS/United States
- P42 ES010337/ES/NIEHS NIH HHS/United States
- P30 DK120515/DK/NIDDK NIH HHS/United States
- U01 AA029019/AA/NIAAA NIH HHS/United States
- R01 DK124318/DK/NIDDK NIH HHS/United States
- K23 DK090303/DK/NIDDK NIH HHS/United States
- U01 DK061734/DK/NIDDK NIH HHS/United States
- R01 DK121378/DK/NIDDK NIH HHS/United States
- R01 DK106419/DK/NIDDK NIH HHS/United States
- P01 HL147835/HL/NHLBI NIH HHS/United States
- K08 DK113109/DK/NIDDK NIH HHS/United States